BMO Capital Markets Boosts Johnson & Johnson (JNJ) Price Target to $161.00
JNJ has been the subject of several other research reports. Cowen reiterated an outperform rating and issued a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reiterated a buy rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group raised their price target on Johnson & Johnson from $157.00 to $160.00 and gave the company a buy rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a sell rating to a hold rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an outperform rating in a research report on Thursday, October 19th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $145.04.
Johnson & Johnson (NYSE JNJ) traded down $1.24 during trading hours on Tuesday, reaching $141.65. The company’s stock had a trading volume of 5,337,900 shares, compared to its average volume of 5,869,776. The stock has a market capitalization of $383,984.28, a PE ratio of 20.02, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC raised its holdings in shares of Johnson & Johnson by 3.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 8,026,652 shares of the company’s stock worth $1,043,545,000 after purchasing an additional 253,568 shares during the period. Karpus Management Inc. purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth about $231,000. Wagner Bowman Management Corp raised its holdings in shares of Johnson & Johnson by 3.2% in the 3rd quarter. Wagner Bowman Management Corp now owns 47,171 shares of the company’s stock worth $6,132,000 after purchasing an additional 1,452 shares during the period. Hikari Tsushin Inc. raised its holdings in shares of Johnson & Johnson by 8.3% in the 3rd quarter. Hikari Tsushin Inc. now owns 53,810 shares of the company’s stock worth $6,996,000 after purchasing an additional 4,130 shares during the period. Finally, Burgundy Asset Management Ltd. raised its holdings in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Burgundy Asset Management Ltd. now owns 3,195,878 shares of the company’s stock valued at $415,496,000 after buying an additional 11,257 shares during the period. 65.89% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/bmo-capital-markets-boosts-johnson-johnson-jnj-price-target-to-161-00/1765978.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.